CFO
DGX icon

Callan Family Office’s Quest Diagnostics DGX Stock Holding History

Callan Family Office’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24M Sell
5,868
-111
-2% -$21.8K 0.02% 538
2026
Q1 		$1.17M Sell
5,979
-1,254
-17% -$244K 0.03% 520
2025
Q4 		$1.26M Buy
7,233
+4,924
+213% +$897K 0.03% 474
2025
Q3 		$440K Sell
2,309
-1,138
-33% -$202K 0.01% 568
2025
Q2 		$619K Buy
+3,447
New +$599K 0.02% 525
2025
Q1 		– Sell
-1,349
Closed -$204K – 577
2024
Q4 		$204K Buy
+1,349
New +$210K 0.01% 606

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Callan Family Office's DGX Position: Q2 2026 in Review

Callan Family Office reduced its Quest Diagnostics (DGX) stake by 1.9% in Q2 2026, selling an estimated $21.8K and leaving 5,868 shares worth $1.24M. The position accounts for 0.02% of the portfolio, ranked #538.

Callan Family Office first reported a position in DGX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.26M in Q4 2025. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Callan Family Office held 5,868 shares of Quest Diagnostics worth $1.24M as of Q2 2026.
  • Callan Family Office sold 111 Quest Diagnostics shares in Q2 2026, an estimated $21.8K.
  • Quest Diagnostics made up 0.02% of Callan Family Office's portfolio in Q2 2026, its #538 holding.
  • Callan Family Office first reported a position in Quest Diagnostics in Q4 2024 and has held it in 6 quarters since.
  • Callan Family Office's Quest Diagnostics position peaked at $1.26M in Q4 2025.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.